Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase I/II trial to investigate the safety and efficacy of OPX-212 in neuromyelitis optica

Next Previous
Trial Profile

A phase I/II trial to investigate the safety and efficacy of OPX-212 in neuromyelitis optica

Status: Planning
Phase of Trial: Phase I/II

Latest Information Update: 25 Sep 2017

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs OPX 212 (Primary)
  • Indications Neuromyelitis optica
  • Focus Adverse reactions; Proof of concept; Therapeutic Use

Most Recent Events

  • 19 Sep 2017 According to a Acer Therapeutics media release, Acer Therapeutics merged with Opexa Therapeutics and the combined company has been named as Acer Therapeutics.
  • 10 Nov 2015 Planned initiation date changed from 1 Aug 2015 to 1 Jan 2016, according to a Opexa Therapeutics media release.
  • 10 Nov 2015 Opexa Therapeutics expects to submit the IND to the US FDA and start this study in the first half of 2016, according to the company media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top